CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas

This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD7 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD7 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary endpoint is the type and incidence of dose limiting toxicity (DLT) within 21 days after CD7 CAR-T cell infusion. A total of 36 subjects is estimated to be enrolled.

Trial Details

NCT ID

NCT06925464

Phase

PHASE1 / PHASE2

Sponsor

Beijing GoBroad Hospital

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

CD7 CAR-T cells infusion

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723
Zhanjiang, Guangdong, China|21.23391,110.38749
Shanghai, Shanghai Municipality, China|31.22222,121.45806
Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Relapsed or refractory CD7-positive T-cell lymphomas that were treated with with standard chemotherapy, with poor prognosis from currently availabl…
Male or female, age 14-70;
Eastern Cooperative Oncology Group (ECOG) Physical Status Score 0-2;
life expectancy is at least 60 days;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →